Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy
- 1 January 2021
- journal article
- research article
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 68 (6), 671-681
- https://doi.org/10.1507/endocrj.ej20-0762
Abstract
Cytotoxic chemotherapy, including cyclophosphamide, vincristine, and dacarbazine (CVD) therapy, is widely used to treat metastatic pheochromocytoma and paraganglioma. Because these diseases are rare, studies are needed to establish treatment strategies. This was a single-center and retrospective study to analyze the efficacy of chemotherapy for patients with metastatic pheochromocytoma and paraganglioma diagnosed in 1983–2020. Clinical characteristics, tumor volume response, biochemical response based on catecholamine level, overall survival, and progression-free survival were evaluated. Patients with a complete response or partial response in tumor volume or catecholamine level were classified as responders. Sixteen patients were administered chemotherapy for a median of 16.5 cycles (interquartile range, 10–42). The tumor volume response was classified as follows: partial response (N = 4), stable disease (N = 9), and progressive disease (N = 3) (disease control rate = 81%). The biochemical responses were as follows: complete response (N = 2), partial response (N = 5), no change (N = 3), and progressive disease (N = 1) (disease control rate = 91%). The 5-year survival rate was 50% (95% confidence interval [CI], 21–74%) and median overall survival was 4.4 years (95% CI, 2.4 years–not reached). Overall survival and progression-free survival between responders and nonresponders were not statistically different. One patient developed myelodysplastic syndrome during CVD therapy. In conclusion, chemotherapy achieved disease control among more than half of patients, although survival did not differ between responders and nonresponders. Further fundamental research and prospective trials are needed to analyze the efficacy of CVD therapy.Keywords
This publication has 27 references indexed in Scilit:
- Sunitinib for the Treatment of Metastatic Paraganglioma and Vasoactive Intestinal Polypeptide-Producing Tumor (VIPoma)Pancreas, 2013
- Targeting VEGF-VEGFR Pathway by Sunitinib in Peripheral Primitive Neuroectodermal Tumor, Paraganglioma and Epithelioid Hemangioendothelioma: Three Case ReportsCase Reports in Oncology, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- External Beam Radiation Therapy (EBRT) for Patients with Malignant Pheochromocytoma and Non-Head and -Neck Paraganglioma: Combination with 131I-MIBGHormone and Metabolic Research, 2012
- Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra‐adrenal paragangliomasCancer, 2011
- Malignant pheochromocytomas and paragangliomas – The importance of a multidisciplinary approachCancer Treatment Reviews, 2011
- Pheochromocytoma and ParagangliomaProgress in Brain Research, 2010
- Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and ParagangliomaJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazineCancer, 2008